Chofn IP, China’s only listed intellectual property agency, on Feb. 9 released a report analyzing the 5,240 requests for trials for invalidation against patent owners at the China National Intellectual Property Administration (CNIPA) in 2021.
The Medicines Patent Pool (MPP) announced on January 20 that it has signed agreements with 27 generic manufacturing companies for the manufacturing of the oral COVID-19 antiviral medication molnupiravir and supply in 105 low- and-middle-income countries (LMICs).
A U.S. appeals court affirmed a win on Monday for Swiss drugmaker Novartis Pharmaceuticals Corp against Chinese generic drugmaker HEC Pharm Co Ltd, finding that a patent covering the blockbuster multiple-sclerosis drug Gilenya is valid and a proposed HEC generic would infringe i
China's National Bureau of Statistics (NBS) and the China Intellectual Property Administration (CNIPA) on December 30 jointly release some data to indicate the growth of China’s patent-intensive industries in 2020.
Artificial intelligence (AI) is a definitive force of the new round of technological revolution and industrial change, and has become the focus of international competition and industrial policy efforts in various countries. Driven by technological innovation, AI has been deeply
